Skip to main content Back to Top
Advertisement

1/8/2021

Mexiletine Hydrochloride Capsules

Products Affected - Description

    • Mexiletine hydrochloride oral capsule, Lannett, 200 mg, bottle, 100 count, NDC 00527-4108-37
    • Mexiletine hydrochloride oral capsule, Lannett, 250 mg, bottle, 100 count, NDC 00527-4109-37

Reason for the Shortage

    • Lannett did not provide a reason for the shortage.
    • Teva has mexiletine capsules on shortage due to a delay in obtaining active pharmaceutical ingredient.

Available Products

    • Mexiletine hydrochloride oral capsule, Lannett, 150 mg, bottle, 100 count, NDC 00527-4107-37
    • Mexiletine hydrochloride oral capsule, Teva, 150 mg, bottle, 100 count, NDC 00093-8739-01
    • Mexiletine hydrochloride oral capsule, Teva, 200 mg, bottle, 100 count, NDC 00093-8740-01
    • Mexiletine hydrochloride oral capsule, Teva, 250 mg, bottle, 100 count, NDC 00093-8741-01

Estimated Resupply Dates

    • Lannett has mexiletine 200 mg and 250 mg capsules on back order and the company estimates release dates in mid-January 2021.

Updated

Updated January 8, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. Created August 10, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.